Nitazoxanide protects against heart failure with preserved ejection and metabolic syndrome induced by high-fat diet (HFD) plus L-NAME "two-hit" in mice.
10.1016/j.apsb.2024.12.040
- Author:
Jiahui CHEN
1
;
Liping ZHANG
1
;
Ting XIE
1
;
Xiao ZHANG
1
;
Congcong PAN
1
;
Fangli SUN
1
;
Wenfeng LI
1
;
Zhijie SUN
1
;
Deli DONG
1
Author Information
1. Department of Pharmacology, China Pharmaceutical University, Nanjing 211198, China.
- Publication Type:Journal Article
- Keywords:
HFpEF;
Heart fibrosis;
Heart hypertrophy;
Hepatic steatosis;
Metabolic syndrome;
Nitazoxanide;
Tizoxanide
- From:
Acta Pharmaceutica Sinica B
2025;15(3):1397-1414
- CountryChina
- Language:English
-
Abstract:
The clinical antiprotozoal drug nitazoxanide has been demonstrated to improve the experimental diabetes mellitus, lipid metabolism disorders, atherosclerosis and inhibit inflammation. Since the pathogenesis of heart failure with preserved ejection (HFpEF) is multifactorial and closely associated with the aforementioned diseases, we aim to study the effect of nitazoxanide on high-fat diet (HFD) plus L-NAME (N ω-nitro-l-arginine methyl ester)-induced HFpEF and metabolic syndrome in mice. We found that oral nitazoxanide improved cardiac hypertrophy, cardiac fibrosis, cardiac diastolic dysfunction, increased blood pressure, impaired exercise tolerance, impaired glucose handling, serum lipid disorders, hepatic steatosis, increased weight of white adipose tissues and kidney fibrosis in HFD + L-NAME-treated mice. In the established HFD + L-NAME-induced HFpEF and metabolic syndrome mouse model, therapeutic treatment with nitazoxanide rescued HFD + L-NAME-induced pathological phenotypes as mentioned above. The in vitro experiments revealed that tizoxanide, the active metabolite of nitazoxanide, increased the basal mitochondria metabolism of cardiomyocytes, inhibited cardiomyocyte hypertrophy and collagen secretion from cardiac fibroblasts, and relaxed phenylephrine- and U46619-induced constriction of rat mesenteric arteries, indicating that the direct effect of tizoxanide might partly contribute to the protective effect of nitazoxanide against HFpEF in vivo. The present study suggests that nitazoxanide might be a potential drug for HFpEF and metabolic syndrome therapy.
